Tritium Enrichment with Manganese Reagents
用锰试剂富集氚
基本信息
- 批准号:10192999
- 负责人:
- 金额:$ 20.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:ADME StudyAddressAmino AcidsAnilineAreaBenignBenzeneCarbon DioxideCarbon MonoxideChemicalsChemistryChlorobenzeneCimetidineCompetenceCorrosivesDataDeuteriumDevelopmentEquilibriumFuransGasesGoalsHealthHistidineHumanHydrogenHydroxidesIbuprofenImidazoleIn SituIronIsotopesKineticsLabelLigandsManganeseManganese CompoundsMediatingMediator of activation proteinMetalsMethodsModificationMolecularNMR SpectroscopyNitrofurantoinNuclearOxidesPeriodicityPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhenolsPhenylalaninePositioning AttributePreparationPropertyPublishingPyrantelPyrazinesPyrazolesPyrrolesReactionReagentRecoveryResearchShipsSolubilitySolventsSourceSpectroscopy, Fourier Transform InfraredSystemTechnologyTestingThermodynamicsThiophenesTolueneTracerTritiumTryptophanWorkXylenebasebenzimidazolecatalystdienefollow-upinnovationinsightirradiationmanganese oxidemeltingnitrobenzenenovelpyridinequinolinesmall moleculesuccess
项目摘要
PROJECT SUMMARY/ABSTRACT
The goal of this project is to prepare tritium labeled compounds using the compound [Mn(CO)3(µ3-OH)]4 (1)
enriched with 3H atoms. Research in the Lacy group using 1 resulted in the discovery that d4-1 facilitates
hydrogen isotope exchange (HIE) with toluene under ambient conditions. This work continues this discovery
toward applications with tritium. The innovation in using 3H enriched 1 for labeling is that 1 is thermodynamically
stable and kinetically inert, except toward HIE, which is the desirable property for a labeling compound/catalyst.
Additionally, it is composed of only Mn iron and carbon monoxide and hydroxide ligands, it does not contain an
organic ligand. Purification of 1 from 3H-labeled material is very simple, which essentially takes advantage of the
low solubility of 1 or facile decomposition under UVA irradiation without solvent degradation. The irradiated
decomposition products are only manganese oxides, CO gas, and H2, all of which can be easily separated from
3H-labeled material. Aim 1 will demonstrate that this is possible. Aim 2 will explore and expand the substrate
scope. Namely, the original discovery by the Lacy group was with toluene. The proposed work will expand the
substrates to those including, but not limited to, substituted benzenes (e.g., chlorobenzene, bromobenzene,
iodobenzene, nitrobenzene, phenol, anisole, aniline, xylenes, mesitylene, hexamethylbenzene, pyridines,
furans, thiophenes, imidazoles, benzimidazoles, pyrrole, pyridines, pyrazoles, pyrazines, conjugated dienes) and
amino acids (e.g., phenylalanine, tryptophan, histidine). Additionally, pharmaceutical targets including, but not
limited to, Ibuprofen, Cimetidine, Pyrantel, Nitrofurantoin. A unique aspect 1 is that it can be used with neat
substrate. Aim 3 will explore fundamental chemical aspects of the labeling chemistry including the
thermochemistry, mechanism, and synthetic modifications that might be required to facilitate Aim 1 and/or Aim
2. The long-term goals are to (i) develop large scale preparation of 1 enriched with 3H, (ii) to do so using 3H2 gas
instead of tritium oxide, and to (iii) develop the technology with 1 for field use in pharmacology. The advantage
of using 3H2 gas is that it is much easier and safe to store and handle than tritium oxide. Pure tritium oxide is
corrosive and undergoes self-radiolysis, which is why it is usually manipulated in very low concentrations. Thus,
technologies that use 3H2 are more desirable than those that use tritium oxide, and efforts toward 1 leverage
and expand the advantages afforded from 3H2. The relevance to human health is that 3H-labeled compounds
are commonly used in pharmacology and the development of 1 in this area reduces the need for toxic and
expensive metal-based labeling strategies.
项目总结/摘要
本项目的目标是利用化合物[Mn(CO)3(µ3-OH)]4(1)制备氚标记化合物
富含3 H原子在Lacy组使用1的研究中发现,d4-1有助于
在环境条件下与甲苯进行氢同位素交换(HIE)。这项工作延续了这一发现
用于氚的应用。使用3 H富集的1进行标记的创新在于,1是手性的。
稳定和动力学惰性,除了对HIE,这是标记化合物/催化剂的期望性质。
此外,它仅由Mn铁和一氧化碳和氢氧化物配体组成,它不含铁。
有机配体从3 H标记的材料中纯化1非常简单,其基本上利用了
1的低溶解度或在UVA照射下容易分解而没有溶剂降解。被照射
分解产物仅为锰氧化物、CO气体和H2,所有这些都可以容易地从
3 H标记物质。目标1将证明这是可能的。AIM 2将探索和扩展基板
scope.也就是说,莱西小组最初的发现是甲苯。拟议的工作将扩大
底物包括,但不限于,取代的苯(例如,氯苯,溴苯,
碘苯,硝基苯,苯酚,苯甲醚,苯胺,二甲苯,均三甲苯,六甲基苯,吡啶,
呋喃、噻吩、咪唑、苯并咪唑、吡咯、吡啶、吡唑、吡嗪、共轭二烯)和
氨基酸(例如,苯丙氨酸、色氨酸、组氨酸)。此外,药物靶标包括但不限于
仅限于伊诺明、西咪替丁、噻嘧啶、呋喃妥因。一个独特的方面1是,它可以与净
衬底目标3将探索标记化学的基本化学方面,包括
热化学、机理和可能需要的合成修饰,以促进目标1和/或目标
2.长期目标是(i)开发富含3 H的1的大规模制备,(ii)使用3 H2气体来这样做
(iii)发展1的技术,供药理学实地使用。的优点
使用3 H2气体的另一个优点是它比氧化氚更容易和安全地储存和处理。纯氧化氚是
它具有腐蚀性,并会发生自辐解,这就是为什么它通常在非常低的浓度下使用。因此,在本发明中,
使用3 H2的技术比使用氚氧化物的技术更理想,并且努力实现1杠杆
并扩展了3 H2提供的优点。与人类健康相关的是,3 H标记的化合物
通常用于药理学,在这一领域开发1减少了对毒性和
昂贵的基于金属的标记策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Charles Lacy其他文献
David Charles Lacy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Charles Lacy', 18)}}的其他基金
Synthesis of CO Dehydrogenase Model Complexes for Catalytic Reductions of CO2
用于催化还原 CO2 的 CO 脱氢酶模型复合物的合成
- 批准号:
8527478 - 财政年份:2013
- 资助金额:
$ 20.83万 - 项目类别:
Synthesis of CO Dehydrogenase Model Complexes for Catalytic Reductions of CO2
用于催化还原 CO2 的 CO 脱氢酶模型复合物的合成
- 批准号:
8652194 - 财政年份:2013
- 资助金额:
$ 20.83万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 20.83万 - 项目类别:
Research Grant